Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1987-7-16
|
| pubmed:abstractText |
We studied the effects on plasma levels of coagulation and fibrinolysis factors of two currently used "sub-50" oral contraceptive preparations (OCs), one containing 750 micrograms lynestrenol and 37.5 micrograms ethinyl estradiol (LYN-EE) and the other containing 150 micrograms levonorgestrel and 30 micrograms ethinyl estradiol (LNG-EE), in groups of about 25 women aged 21 +/- 2 years. After 3 months, plasminogen levels increased in the two experimental groups (LYN-EE and LNG-EE), by 40% and 32%, respectively. This change was positively correlated with changes in ceruloplasmin levels, indicating that an estrogenic effect might be involved. Histidine-rich glycoprotein concentration decreased by 26% and 16%, respectively. Tissue-type plasminogen activator (t-PA) activity increased by 260% and 167%; t-PA antigen decreased by 12% and 18%, and t-PA inhibitor activity decreased by 31% and 32%, respectively. In the coagulation system, in both groups factor XII increased by 47% and 34%, respectively. The main inhibitor of factor XII, C1-inactivator, decreased slightly, but this was significant only in the LNG-EE group. The von Willebrand factor antigen fell by 8% and 9%, whereas factor VIII activity did not change. Antithrombin III antigen decreased by 14% in both groups. Factor IX activity increased by 15% and 21%. The difference in hormonal effects of both preparations was reflected by the increases in sex hormone binding globulin (by 130% and 21%) and ceruloplasmin (by 98% and 51%), indicating that LYN-EE had a more estrogenic potency than LNG-EE. In a control group of 25 matched subjects, who were observed simultaneously, we found no significant changes.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Contraceptives, Oral, Combined,
http://linkedlifedata.com/resource/pubmed/chemical/Ethinyl Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Levonorgestrel,
http://linkedlifedata.com/resource/pubmed/chemical/Lynestrenol,
http://linkedlifedata.com/resource/pubmed/chemical/Norgestrel,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Sex Hormone-Binding Globulin,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/histidine-rich proteins,
http://linkedlifedata.com/resource/pubmed/chemical/von Willebrand Factor
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0022-2143
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
109
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
631-6
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3108429-Adult,
pubmed-meshheading:3108429-Blood Coagulation,
pubmed-meshheading:3108429-Blood Proteins,
pubmed-meshheading:3108429-Contraceptives, Oral, Combined,
pubmed-meshheading:3108429-Ethinyl Estradiol,
pubmed-meshheading:3108429-Female,
pubmed-meshheading:3108429-Fibrinolysis,
pubmed-meshheading:3108429-Humans,
pubmed-meshheading:3108429-Levonorgestrel,
pubmed-meshheading:3108429-Lynestrenol,
pubmed-meshheading:3108429-Norgestrel,
pubmed-meshheading:3108429-Plasminogen,
pubmed-meshheading:3108429-Proteins,
pubmed-meshheading:3108429-Sex Hormone-Binding Globulin,
pubmed-meshheading:3108429-Tissue Plasminogen Activator,
pubmed-meshheading:3108429-von Willebrand Factor
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|